ЛАМБЕРТ Джон (US),О'ЛИРИ Джеймс Дж. (US),ШИНДЛЕР Джоанн Элизабет Сара (US),УИТМАН Стивен (US),КИН Альберт (US),ОЛИРИ Джеймс Дж. (US)
申请号：
RU2012120691/15
公开号：
RU2012120691A
申请日:
2010.10.21
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating cancer, comprising pre-treating a subject in need of treatment with prophylactic corticosteroids and then administering an anti-CD56-maytansinoid conjugate by infusion with an initial infusion rate of 1 mg / min. or lower according to a scheme selected from the group consisting of: (1) an amount of at least approximately 90 mg / mv day 1 and day 8 every three weeks； and (2) amounts of at least about 30 mg / mv day 1, day 2, and day 3 every three weeks. The method according to claim 1, characterized in that the treatment of cancer further comprises treating mammalian tumors. The method according to claim 2, characterized in that the anti-CD56-maytansinoid conjugate is IMGN901.4. The method according to claim 2, characterized in that the anti-CD56-maytansinoid conjugate is administered in a dose selected from the group consisting of: (a) at least about 90 mg / mv day 1 and day 8 every three weeks, and (b ) at least about 112 mg / mv day 1 and day 8 every three weeks. The method according to claim 2, characterized in that the anti-CD56-maytansinoid conjugate is administered in a dose selected from the group consisting of: (a) at least about 30 mg / mv day 1, day 2 and day 3 every three weeks, (b) at least about 36 mg / mv day 1, day 2 and day 3 every three weeks, (c) at least about 48 mg / mv day 1, day 2 and day 3 every three weeks, (g) at least about 60 mg / mv day 1, day 2 and day 3 every three weeks, and (d) at least about 75 mg / mv day 1, day 2 and day 3 every three weeks. The method according to claim 2, characterized in that the cancer is selected from the group consisting of small cell lung cancer； ovarian cancer； non-small cell lung cancer； neuroendocrine �1. Способ лечения рака, включающий предварительное лечение субъекта, нуждающегося в лечении, профилактическим назначением кортикостероидов, а затем введением конъюгата анти-CD56-майтанзиноид при помощи инфузии с начальной скоростью инфузии 1 мг/мин. или ниже по схеме, выбранной из гр
